In our study, sequencing and network pharmacology analysis suggested that STAT3 represents a poteneially important target of Lan C action on cholangiocarcinoma cells, confirmed in subsequent WB and in vivo experiments. The gene discussed is STAT3; the disease is cholangiocarcinoma.